PSTV Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

1.40M

-1.06%

-0.040

-91.84%

1.35M

+27.51%

-0.035

-93.83%

1.52M

+9.26%

-0.035

+438.46%

Estimates Revision

The market is revising Upward the revenue expectations for Plus Therapeutics, Inc. (PSTV) for FY2025, with the revenue forecasts being adjusted by 5.83% over the past three months. During the same period, the stock price has changed by -19.88%.

Revenue Estimates for FY2025

Revise Upward

+5.83%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-25%

In Past 3 Month

Stock Price

Go Down

-19.88%

In Past 3 Month

4 Analyst Rating

Wall Street analysts forecast PSTV stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PSTV is 7.75 USD with a low forecast of 2.00 USD and a high forecast of 21.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

4 Buy

0 Hold

0 Sell

Strong Buy

Current: 0.000

Low

2.00

Averages

7.75

High

21.00

Current: 0.000

Low

2.00

Averages

7.75

High

21.00

H.C. Wainwright

Buy

downgrade

$3 -> $2

2025-11-03

Reason

H.C. Wainwright

Price Target

$3 -> $2

2025-11-03

downgrade

Buy

Reason

H.C. Wainwright lowered the firm's price target on Plus Therapeutics to $2 from $3 and keeps a Buy rating on the shares. The firm cites dilution associated with the equity raise for the target drop.

D. Boral Capital

Jason Kolbert

Hold

Buy

upgrade

2025-09-03

Reason

D. Boral Capital

Jason Kolbert

Price Target

2025-09-03

upgrade

Hold

Buy

Reason

D. Boral Capital analyst Jason Kolbert upgraded Plus Therapeutics to Buy from Hold with a $5 price target. The firm, which previously had lowered its rating in May on concerns that the company was likely to execute a reverse split, says it seems those concerns \"may have faded\" for the moment and also cites the progress the company has been making on the diagnostics side. With catalysts such as a diagnostics launch, the firm sees the stock being back up over the \"critical $1.00 mark,\" the analyst added.

Maxim

Buy

downgrade

$4 -> $3

2025-08-18

Reason

Maxim

Price Target

$4 -> $3

2025-08-18

downgrade

Buy

Reason

Maxim lowered the firm's price target on Plus Therapeutics to $3 from $4 and keeps a Buy rating on the shares. The firm is updating its model to reflect the company's equity dilution but also notes that its restructuring is a positive, transforming a highly dilutive equity financing into a less dilutive financing that can be thought of as 35M prefunded warrants plus $15M in debt, the analyst tells investors in a research note.

H.C. Wainwright

Sean Lee

Buy

downgrade

2025-06-27

Reason

H.C. Wainwright

Sean Lee

Price Target

2025-06-27

downgrade

Buy

Reason

H.C. Wainwright analyst Sean Lee lowered the firm's price target on Plus Therapeutics to $3 from $5.50 and keeps a Buy rating on the shares. The firm cites the restructured number of outstanding shares and warrants associated with the March equity offering for the target cut.

Ascendiant Capital

Edward Woo

Strong Buy

Maintains

$19 → $20

2025-04-21

Reason

Ascendiant Capital

Edward Woo

Price Target

$19 → $20

2025-04-21

Maintains

Strong Buy

Reason

D. Boral Capital

Jason Kolbert

Strong Buy

Maintains

2025-03-28

Reason

D. Boral Capital

Jason Kolbert

Price Target

2025-03-28

Maintains

Strong Buy

Reason

Valuation Metrics

The current forward P/E ratio for Plus Therapeutics Inc (PSTV.O) is -3.83, compared to its 5-year average forward P/E of -1.27. For a more detailed relative valuation and DCF analysis to assess Plus Therapeutics Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-1.27

Current PE

-3.83

Overvalued PE

-0.37

Undervalued PE

-2.18

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-0.91

Current EV/EBITDA

-4.50

Overvalued EV/EBITDA

0.34

Undervalued EV/EBITDA

-2.16

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

3.39

Current PS

12.70

Overvalued PS

9.99

Undervalued PS

-3.21

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

PSTV News & Events

Events Timeline

No data

News

3.5

2025-11-24Newsfilter

Plus Therapeutics Advances REYOBIQ Clinical Plans Following FDA Type B Meeting

6.0

2025-11-21Benzinga

Palo Alto Set to Surge by 30%? Check Out 10 Leading Analyst Predictions for Friday

6.0

2025-11-21Benzinga

Ascendiant Capital Reaffirms Buy Rating on Plus Therapeutics, Adjusts Price Target to $19

People Also Watch

Frequently Asked Questions

What is Plus Therapeutics Inc (PSTV) stock price today?

The current price of PSTV is 0.598 USD — it has decreased -1.65 % in the last trading day.

What is Plus Therapeutics Inc (PSTV)'s business?

Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company. The Company is engaged in developing targeted radiotherapeutics for difficult-to-treat cancers of the central nervous system. Combining image-guided local beta radiation and targeted drug delivery approaches, it is advancing a pipeline of product candidates with lead programs in leptomeningeal metastases (LM) and recurrent glioblastoma (GBM). Its lead radiotherapeutic candidate, REYOBIQ (rhenium (186Re) obisbemeda), is designed specifically for CNS cancers including GBM, LM, and pediatric brain cancers (PBC) by direct localized delivery utilizing approved standard-of-care tissue access such as with convection-enhanced delivery (CED) and intraventricular brain (Ommaya reservoir) catheters. Its radiotherapeutic candidate, Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere (188RNL-BAM), is designed to treat many solid organ cancers including primary and secondary liver cancers via intra-arterial injections.

What is the price predicton of PSTV Stock?

What is Plus Therapeutics Inc (PSTV)'s revenue for the last quarter?

Plus Therapeutics Inc revenue for the last quarter amounts to 1.40M USD, decreased -4.05 % YoY.

What is Plus Therapeutics Inc (PSTV)'s earnings per share (EPS) for the last quarter?

Plus Therapeutics Inc. EPS for the last quarter amounts to -0.04 USD, decreased -89.19 % YoY.

What changes have occurred in the market's expectations for Plus Therapeutics Inc (PSTV)'s fundamentals?

How many employees does Plus Therapeutics Inc (PSTV). have?

Plus Therapeutics Inc (PSTV) has 21 emplpoyees as of January 08 2026.

What is Plus Therapeutics Inc (PSTV) market cap?

Today PSTV has the market capitalization of 83.53M USD.